Hypertensive treatment in patients with metabolic syndrome.
The prevalence of obesity, hypertension, and type 2 diabetes mellitus-in other words, the metabolic syndrome-is increasing in the United States. In this setting, it is important to understand the effects of antihypertensives on parameters of the metabolic syndrome in addition to glucose metabolism. Here the authors review pertinent clinical studies.
Medical Service, Department of Veterans Affairs, Northern California Health Care System, Mather, California 95655, USA. david.siegel@va.gov
David
D
Siegel
Arthur L M
AL
Swislocki
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D024821:Metabolic Syndrome / Q000150:complications / Q000188:drug therapy*
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers